Literature DB >> 1717281

Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69.

P Sánchez-Mateos1, F Sánchez-Madrid.   

Abstract

Human activation inducer molecule (AIM/CD69), a dimeric glycoprotein structure of 33 and 27 kDa, is the earliest inducible cell surface antigen expressed during lymphocyte activation and is implicated in the induction of T and B cell proliferative responses. Cross-competition monoclonal antibodies (mAb) binding assays have allowed the definition of four antigenic epitopes. Three of them (antigenic sites E1-3) are extracellular while the fourth (site I) is a sequential epitope localized intracellularly and highly conserved interspecies. Site E1 is shown to be an immunodominant antigenic determinant closely related to a functional domain of AIM important for triggering of T cell proliferation. Studies of peptide fragmentation of the two isolated AIM subunits with different proteases have demonstrated that both AIM chains are differentially glycosylated forms of a single 24-kDa core protein. Moreover, the two denatured and isolated AIM chains share common epitope(s) as demonstrated by their reactivity with an mAb by both Western blot analysis and immunoprecipitation of the separated AIM subunits. Biosynthesis studies revealed the rapid appearance of two intermediate precursor forms of 29 and 26 kDa which arise from the 24-kDa unglycosylated AIM polypeptide. This 24-kDa unglycosylated form could be also precipitated from iodinated cells pretreated with tunicamycin, indicating that glycosylation of the protein was neither required for AIM cell surface expression nor for acquisition of external epitopes E1-E3. Cell treatment with pronase resulted in the loss of the external epitopes E1-3 and the generation of a proteolytic peptide of 16 kDa that could be precipitated by the anti-AIM mAb specific for the internal site I. This proteolytic fragment retained the transmembrane and cytoplasmic regions of the molecule where both epitope I and phosphorylation sites reside. These results demonstrate that AIM is an integral membrane homodimeric glycoprotein with a large cytoplasmic domain probably involved in the activation signals transduced through this molecule to lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717281     DOI: 10.1002/eji.1830211005

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Blockade of T-cell activation by dithiocarbamates involves novel mechanisms of inhibition of nuclear factor of activated T cells.

Authors:  S Martínez-Martínez; P Gómez del Arco; A L Armesilla; J Aramburu; C Luo; A Rao; J M Redondo
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

2.  Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12.

Authors:  C Cambiaggi; M T Scupoli; T Cestari; F Gerosa; G Carra; G Tridente; R S Accolla
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.

Authors:  F Borrego; M J Robertson; J Ritz; J Peña; R Solana
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

4.  Rapid mitogen-induced aminopeptidase N surface expression in human T cells is dominated by mechanisms independent of de novo protein biosynthesis.

Authors:  U Lendeckel; T Wex; A Ittenson; M Arndt; K Frank; O Mayboroda; W Schubert; S Ansorge
Journal:  Immunobiology       Date:  1997-06       Impact factor: 3.144

5.  Induction of CD69 expression by cagPAI-positive Helicobacter pylori infection.

Authors:  Naoki Mori; Chie Ishikawa; Masachika Senba
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

6.  The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1.

Authors:  Hortensia de la Fuente; Aranzazu Cruz-Adalia; Gloria Martinez Del Hoyo; Danay Cibrián-Vera; Pedro Bonay; Daniel Pérez-Hernández; Jesús Vázquez; Pilar Navarro; Ricardo Gutierrez-Gallego; Marta Ramirez-Huesca; Pilar Martín; Francisco Sánchez-Madrid
Journal:  Mol Cell Biol       Date:  2014-04-21       Impact factor: 4.272

7.  Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production.

Authors:  Isidoro González-Alvaro; Carmen Domínguez-Jiménez; Ana M Ortiz; Vanessa Núñez-González; Pedro Roda-Navarro; Elena Fernández-Ruiz; David Sancho; Francisco Sánchez-Madrid
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors.

Authors:  M López-Cabrera; A G Santis; E Fernández-Ruiz; R Blacher; F Esch; P Sánchez-Mateos; F Sánchez-Madrid
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

9.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

10.  Enhanced antitumor immunity in mice deficient in CD69.

Authors:  Enric Esplugues; David Sancho; Javier Vega-Ramos; Carlos Martínez; Uta Syrbe; Alf Hamann; Pablo Engel; Francisco Sánchez-Madrid; Pilar Lauzurica
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.